The European Medicines Agency (EMA) will launch a new and improved version of EudraVigilance, the European information system of suspected adverse reactions to medicines that are authorised or being studied in clinical trials in the European Economic Area (EEA). The new version of EudraVigilance will go live on 22 November 2017 with enhanced functionalities for reporting and analysing suspected adverse reactions.
Time to train and prepare for implementation of the NEW EudraVigilance System and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format.
The complete EMA official announcement can be found here.
